Comprehensive Physiology Wiley Online Library

Immune and Inflammatory Role in Renal Disease

Full Article on Wiley Online Library


Chronic and acute renal diseases, irrespective of the initiating cause, have inflammation and immune system activation as a common underlying mechanism. The purpose of this review is to provide a broad overview of immune cells and inflammatory proteins that contribute to the pathogenesis of renal disease, and to discuss some of the physiological changes that occur in the kidney as a result of immune system activation. An overview of common forms of acute and chronic renal disease is provided, followed by a discussion of common therapies that have anti‐inflammatory or immunosuppressive effects in the treatment of renal disease. © 2013 American Physiological Society. Compr Physiol 3:957‐976, 2013.

Comprehensive Physiology offers downloadable PowerPoint presentations of figures for non-profit, educational use, provided the content is not modified and full credit is given to the author and publication.

Download a PowerPoint presentation of all images

Figure 1. Figure 1.

Immune system activation and inflammation have a central role in the pathogenesis of acute kidney injury (AKI) and chronic kidney disease (CKD).

Figure 2. Figure 2.

Immune system components and proteins implicated in the pathogenesis of renal disease. The overlap represents components involved in cross‐talk between innate and adaptive immunity.

Figure 3. Figure 3.

Schematic of inflammatory events involved in the progression of diabetic nephropathy.

Figure 4. Figure 4.

Schematic of contribution of T cells and cytokines in hypertension.

Figure 5. Figure 5.

Schematic of inflammatory events involved in the progression of renal disease.

Figure 1.

Immune system activation and inflammation have a central role in the pathogenesis of acute kidney injury (AKI) and chronic kidney disease (CKD).

Figure 2.

Immune system components and proteins implicated in the pathogenesis of renal disease. The overlap represents components involved in cross‐talk between innate and adaptive immunity.

Figure 3.

Schematic of inflammatory events involved in the progression of diabetic nephropathy.

Figure 4.

Schematic of contribution of T cells and cytokines in hypertension.

Figure 5.

Schematic of inflammatory events involved in the progression of renal disease.

 1. Abbate M, Zoja C, Corna D, Capitanio M, Bertani T, Remuzzi G. In progressive nephropathies, overload of tubular cells with filtered proteins translates glomerular permeability dysfunction into cellular signals of interstitial inflammation. J Am Soc Nephrol 9: 1213‐1224, 1998.
 2. Agarwal R. Anti‐inflammatory effects of short‐term pioglitazone therapy in men with advanced diabetic nephropathy. Am J Physiol Renal Physiol 290: F600‐F605, 2006.
 3. Araki S, Haneda M, Koya D, Sugimoto T, Isshiki K, Chin‐Kanasaki M, Uzu T, Kashiwagi A. Predictive impact of elevated serum level of IL‐18 for early renal dysfunction in type 2 diabetes: An observational follow‐up study. Diabetologia 50: 867‐873, 2007.
 4. Asano M, Toda M, Sakaguchi N, Sakaguchi S. Autoimmune disease as a consequence of developmental abnormality of a T cell subpopulation. J Exp Med 184: 387‐396, 1996.
 5. Atkinson C, Qiao F, Song H, Gilkeson GS, Tomlinson S. Low‐dose targeted complement inhibition protects against renal disease and other manifestations of autoimmune disease in MRL/lpr mice. J Immunol 180: 1231‐1238, 2008.
 6. Bagavant H, Deshmukh US, Wang H, Ly T, Fu SM. Role for nephritogenic T cells in lupus glomerulonephritis: Progression to renal failure is accompanied by T cell activation and expansion in regional lymph nodes. J Immunol 177: 8258‐8265, 2006.
 7. Bakris G, Viberti G, Weston WM, Heise M, Porter LE, Freed MI. Rosiglitazone reduces urinary albumin excretion in type II diabetes. J Hum Hypertens 17: 7‐12, 2003.
 8. Banas B, Luckow B, Moller M, Klier C, Nelson PJ, Schadde E, Brigl M, Halevy D, Holthofer H, Reinhart B, Schlondorff D. Chemokine and chemokine receptor expression in a novel human mesangial cell line. J Am Soc Nephrol 10: 2314‐2322, 1999.
 9. Barhoumi T, Kasal DA, Li MW, Shbat L, Laurant P, Neves MF, Paradis P, Schiffrin EL. T regulatory lymphocytes prevent angiotensin II‐induced hypertension and vascular injury. Hypertension 57: 469‐476, 2011.
 10. Bastard JP, Jardel C, Bruckert E, Blondy P, Capeau J, Laville M, Vidal H, Hainque B. Elevated levels of interleukin 6 are reduced in serum and subcutaneous adipose tissue of obese women after weight loss. J Clin Endocrinol Metab 85: 3338‐3342, 2000.
 11. Beasley D, Dinarello CA, Cannon JG. Interleukin‐1 induces natriuresis in conscious rats: Role of renal prostaglandins. Kidney Int 33: 1059‐1065, 1988.
 12. Berger SP, Daha MR. Complement in glomerular injury. Semin Immunopathol 29: 375‐384, 2007.
 13. Bierhaus A, Schiekofer S, Schwaninger M, Andrassy M, Humpert PM, Chen J, Hong M, Luther T, Henle T, Kloting I, Morcos M, Hofmann M, Tritschler H, Weigle B, Kasper M, Smith M, Perry G, Schmidt AM, Stern DM, Haring HU, Schleicher E, Nawroth PP. Diabetes‐associated sustained activation of the transcription factor nuclear factor‐kappaB. Diabetes 50: 2792‐2808, 2001.
 14. Boesen EI, Williams DL, Pollock JS, Pollock DM. Immunosuppression with mycophenolate mofetil attenuates the development of hypertension and albuminuria in deoxycorticosterone acetate‐salt hypertensive rats. Clin Exp Pharmacol Physiol 37: 1016‐1022, 2010.
 15. Bolignano D, Zoccali C. Glitazones in chronic kidney disease: Potential and concerns. Nutr Metab Cardiovasc Dis 22: 167‐175, 2012.
 16. Bolton WK. Goodpasture's syndrome. Kidney Int 50: 1753‐1766, 1996.
 17. Bomback AS, Derebail VK, McGregor JG, Kshirsagar AV, Falk RJ, Nachman PH. Rituximab therapy for membranous nephropathy: A systematic review. Clin J Am Soc Nephrol 4: 734‐744, 2009.
 18. Bomback AS, Smith RJ, Barile GR, Zhang Y, Heher EC, Herlitz L, Stokes MB, Markowitz GS, D'Agati VD, Canetta PA, Radhakrishnan J, Appel GB. Eculizumab for dense deposit disease and C3 glomerulonephritis. Clin J Am Soc Nephrol 7: 748‐756, 2012.
 19. Botto M. C1q knock‐out mice for the study of complement deficiency in autoimmune disease. Exp Clin Immunogenet 15: 231‐234, 1998.
 20. Bouloumie A, Marumo T, Lafontan M, Busse R. Leptin induces oxidative stress in human endothelial cells. FASEB J 13: 1231‐1238, 1999.
 21. Boumpas DT, Furie R, Manzi S, Illei GG, Wallace DJ, Balow JE, Vaishnaw A. A short course of BG9588 (anti‐CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum 48: 719‐727, 2003.
 22. Brands MW, Banes‐Berceli AK, Inscho EW, Al‐Azawi H, Allen AJ, Labazi H. Interleukin 6 knockout prevents angiotensin II hypertension: Role of renal vasoconstriction and janus kinase 2/signal transducer and activator of transcription 3 activation. Hypertension 56: 879‐884, 2010.
 23. Bravo Y, Quiroz Y, Ferrebuz A, Vaziri ND, Rodriguez‐Iturbe B. Mycophenolate mofetil administration reduces renal inflammation, oxidative stress, and arterial pressure in rats with lead‐induced hypertension. Am J Physiol Renal Physiol 293: F616‐F623, 2007.
 24. Brunskill NJ. Albumin handling by proximal tubular cells: Mechanisms and mediators. Nephrol Dial Transplant 15(Suppl 6): 39‐40, 2000.
 25. Burne MJ, Daniels F, El GA, Mauiyyedi S, Colvin RB, O'Donnell MP, Rabb H. Identification of the CD4(+) T cell as a major pathogenic factor in ischemic acute renal failure. J Clin Invest 108: 1283‐1290, 2001.
 26. Bustos C, Gonzalez E, Muley R, Alonso JL, Egido J. Increase of tumour necrosis factor alpha synthesis and gene expression in peripheral blood mononuclear cells of children with idiopathic nephrotic syndrome. Eur J Clin Invest 24: 799‐805, 1994.
 27. Butler DM, Maini RN, Feldmann M, Brennan FM. Modulation of proinflammatory cytokine release in rheumatoid synovial membrane cell cultures. Comparison of monoclonal anti TNF‐alpha antibody with the interleukin‐1 receptor antagonist. Eur Cytokine Netw 6: 225‐230, 1995.
 28. Cao Z, Bonnet F, Candido R, Nesteroff SP, Burns WC, Kawachi H, Shimizu F, Carey RM, De GM, Cooper ME. Angiotensin type 2 receptor antagonism confers renal protection in a rat model of progressive renal injury. J Am Soc Nephrol 13: 1773‐1787, 2002.
 29. Chagnac A, Weinstein T, Korzets A, Ramadan E, Hirsch J, Gafter U. Glomerular hemodynamics in severe obesity. Am J Physiol Renal Physiol 278: F817‐F822, 2000.
 30. Chan TM, Li FK, Tang CS, Wong RW, Fang GX, Ji YL, Lau CS, Wong AK, Tong MK, Chan KW, Lai KN. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong‐Guangzhou Nephrology Study Group. N Engl J Med 343: 1156‐1162, 2000.
 31. Cherney DZ, Lai V, Scholey JW, Miller JA, Zinman B, Reich HN. Effect of direct renin inhibition on renal hemodynamic function, arterial stiffness, and endothelial function in humans with uncomplicated type 1 diabetes: A pilot study. Diabetes Care 33: 361‐365, 2010.
 32. Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 344: 907‐916, 2001.
 33. Coppo M, Bandinelli M, Berni A, Galastri S, Abbate R, Poggesi L, Marra F, Gensini GF, Boddi M. Ang II Upregulation of the T‐lymphocyte renin‐angiotensin system is amplified by low‐grade inflammation in human hypertension. Am J Hypertens 24: 716‐723, 2011.
 34. Couser WG. Glomerulonephritis. Lancet 353: 1509‐1515, 1999.
 35. Crowley SD, Song YS, Lin EE, Griffiths R, Kim HS, Ruiz P. Lymphocyte responses exacerbate angiotensin II‐dependent hypertension. Am J Physiol Regul Integr Comp Physiol 298: R1089‐R1097, 2010.
 36. Curat CA, Wegner V, Sengenes C, Miranville A, Tonus C, Busse R, Bouloumie A. Macrophages in human visceral adipose tissue: Increased accumulation in obesity and a source of resistin and visfatin. Diabetologia 49: 744‐747, 2006.
 37. Dalla VM, Mussap M, Gallina P, Bruseghin M, Cernigoi AM, Saller A, Plebani M, Fioretto P. Acute‐phase markers of inflammation and glomerular structure in patients with type 2 diabetes. J Am Soc Nephrol 16(Suppl 1): S78‐S82, 2005.
 38. Daoussis D, Andonopoulos AP, Liossis SN. Targeting CD40L: A promising therapeutic approach. Clin Diagn Lab Immunol 11: 635‐641, 2004.
 39. de Jesus ST, Volpini RA, Francescato HD, Costa RS, da Silva CG, Coimbra TM. Effects of resveratrol on glycerol‐induced renal injury. Life Sci 81: 647‐656, 2007.
 40. De Miguel C, Das S, Lund H, Mattson DL. T lymphocytes mediate hypertension and kidney damage in Dahl salt‐sensitive rats. Am J Physiol Regul Integr Comp Physiol 298: R1136‐R1142, 2010.
 41. De MC, Das S, Lund H, Mattson DL. T lymphocytes mediate hypertension and kidney damage in Dahl salt‐sensitive rats. Am J Physiol Regul Integr Comp Physiol 298: R1136‐R1142, 2010.
 42. Desmouliere A, Geinoz A, Gabbiani F, Gabbiani G. Transforming growth factor‐beta 1 induces alpha‐smooth muscle actin expression in granulation tissue myofibroblasts and in quiescent and growing cultured fibroblasts. J Cell Biol 122: 103‐111, 1993.
 43. Dick GM, Katz PS, Farias M, III, Morris M, James J, Knudson JD, Tune JD. Resistin impairs endothelium‐dependent dilation to bradykinin, but not acetylcholine, in the coronary circulation. Am J Physiol Heart Circ Physiol 291: H2997‐H3002, 2006.
 44. DiPetrillo K, Coutermarsh B, Gesek FA. Urinary tumor necrosis factor contributes to sodium retention and renal hypertrophy during diabetes. Am J Physiol Renal Physiol 284: F113‐F121, 2003.
 45. Do Amaral CL, Francescato HD, Coimbra TM, Costa RS, Darin JD, Antunes LM, Bianchi ML. Resveratrol attenuates cisplatin‐induced nephrotoxicity in rats. Arch Toxicol 82: 363‐370, 2008.
 46. Dohi K, Iwano M, Muraguchi A, Horii Y, Hirayama T, Ogawa S, Shiiki H, Hirano T, Kishimoto T, Ishikawa H. The prognostic significance of urinary interleukin 6 in IgA nephropathy. Clin Nephrol 35: 1‐5, 1991.
 47. Donadelli R, Abbate M, Zanchi C, Corna D, Tomasoni S, Benigni A, Remuzzi G, Zoja C. Protein traffic activates NF‐kB gene signaling and promotes MCP‐1‐dependent interstitial inflammation. Am J Kidney Dis 36: 1226‐1241, 2000.
 48. Duffield JS. Macrophages and immunologic inflammation of the kidney. Semin Nephrol 30: 234‐254, 2010.
 49. Dzielak DJ. Immune mechanisms in experimental and essential hypertension. Am J Physiol 260: R459‐R467, 1991.
 50. Eardley KS, Zehnder D, Quinkler M, Lepenies J, Bates RL, Savage CO, Howie AJ, Adu D, Cockwell P. The relationship between albuminuria, MCP‐1/CCL2, and interstitial macrophages in chronic kidney disease. Kidney Int 69: 1189‐1197, 2006.
 51. Einav S, Pozdnyakova OO, Ma M, Carroll MC. Complement C4 is protective for lupus disease independent of C3. J Immunol 168: 1036‐1041, 2002.
 52. Elbatarny HS, Netherton SJ, Ovens JD, Ferguson AV, Maurice DH. Adiponectin, ghrelin, and leptin differentially influence human platelet and human vascular endothelial cell functions: Implication in obesity‐associated cardiovascular diseases. Eur J Pharmacol 558: 7‐13, 2007.
 53. Elmarakby AA, Quigley JE, Imig JD, Pollock JS, Pollock DM. TNF‐alpha inhibition reduces renal injury in DOCA‐salt hypertensive rats. Am J Physiol Regul Integr Comp Physiol 294: R76‐R83, 2008.
 54. Elmarakby AA, Quigley JE, Olearczyk JJ, Sridhar A, Cook AK, Inscho EW, Pollock DM, Imig JD. Chemokine receptor 2b inhibition provides renal protection in angiotensin II ‐ salt hypertension. Hypertension 50: 1069‐1076, 2007.
 55. Elmarakby AA, Quigley JE, Pollock DM, Imig JD. Tumor necrosis factor alpha blockade increases renal Cyp2c23 expression and slows the progression of renal damage in salt‐sensitive hypertension. Hypertension 47: 557‐562, 2006.
 56. Endo M, Ohi H, Ohsawa I, Fujita T, Matsushita M, Fujita T. Glomerular deposition of mannose‐binding lectin (MBL) indicates a novel mechanism of complement activation in IgA nephropathy. Nephrol Dial Transplant 13: 1984‐1990, 1998.
 57. Eremina V, Quaggin SE. The role of VEGF‐A in glomerular development and function. Curr Opin Nephrol Hypertens 13: 9‐15, 2004.
 58. Esteban V, Lorenzo O, Ruperez M, Suzuki Y, Mezzano S, Blanco J, Kretzler M, Sugaya T, Egido J, Ruiz‐Ortega M. Angiotensin II, via AT1 and AT2 receptors and NF‐kappaB pathway, regulates the inflammatory response in unilateral ureteral obstruction. J Am Soc Nephrol 15: 1514‐1529, 2004.
 59. Falk RJ, Jennette JC. ANCA small‐vessel vasculitis. J Am Soc Nephrol 8: 314‐322, 1997.
 60. Feldman DL, Jin L, Xuan H, Contrepas A, Zhou Y, Webb RL, Mueller DN, Feldt S, Cumin F, Maniara W, Persohn E, Schuetz H, Jan Danser AH, Nguyen G. Effects of aliskiren on blood pressure, albuminuria, and (pro)renin receptor expression in diabetic TG(mRen‐2)27 rats. Hypertension 52: 130‐136, 2008.
 61. Ferrario F, Castiglione A, Colasanti G, Barbiano di BG, Bertoli S, D'Amico G. The detection of monocytes in human glomerulonephritis. Kidney Int 28: 513‐519, 1985.
 62. Flodstrom M, Shi FD, Sarvetnick N, Ljunggren HG. The natural killer cell – friend or foe in autoimmune disease? Scand J Immunol 55: 432‐441, 2002.
 63. Floege J, Burns MW, Alpers CE, Yoshimura A, Pritzl P, Gordon K, Seifert RA, Bowen‐Pope DF, Couser WG, Johnson RJ. Glomerular cell proliferation and PDGF expression precede glomerulosclerosis in the remnant kidney model. Kidney Int 41: 297‐309, 1992.
 64. Floege J, Eitner F. Immune modulating therapy for IgA nephropathy: Rationale and evidence. Semin Nephrol 28: 38‐47, 2008.
 65. Floege J, van RC, Boor P, Ostendorf T. The role of PDGF‐D in mesangioproliferative glomerulonephritis. Contrib Nephrol 157: 153‐158, 2007.
 66. Fornoni A, Ijaz A, Tejada T, Lenz O. Role of inflammation in diabetic nephropathy. Curr Diabetes Rev 4: 10‐17, 2008.
 67. Fukami K, Ueda S, Yamagishi S, Kato S, Inagaki Y, Takeuchi M, Motomiya Y, Bucala R, Iida S, Tamaki K, Imaizumi T, Cooper ME, Okuda S. AGEs activate mesangial TGF‐beta‐Smad signaling via an angiotensin II type I receptor interaction. Kidney Int 66: 2137‐2147, 2004.
 68. Furuichi K, Wada T, Iwata Y, Kitagawa K, Kobayashi K, Hashimoto H, Ishiwata Y, Asano M, Wang H, Matsushima K, Takeya M, Kuziel WA, Mukaida N, Yokoyama H. CCR2 signaling contributes to ischemia‐reperfusion injury in kidney. J Am Soc Nephrol 14: 2503‐2515, 2003.
 69. Garber SL, Mirochnik Y, Brecklin CS, Unemori EN, Singh AK, Slobodskoy L, Grove BH, Arruda JA, Dunea G. Relaxin decreases renal interstitial fibrosis and slows progression of renal disease. Kidney Int 59: 876‐882, 2001.
 70. Garin EH, Diaz LN, Mu W, Wasserfall C, Araya C, Segal M, Johnson RJ. Urinary CD80 excretion increases in idiopathic minimal‐change disease. J Am Soc Nephrol 20: 260‐266, 2009.
 71. Geiler J, Buch M, McDermott MF. Anti‐TNF treatment in rheumatoid arthritis. Curr Pharm Des 17: 3141‐3154, 2011.
 72. Genovese MC, McKay JD, Nasonov EL, Mysler EF, da Silva NA, Alecock E, Woodworth T, Gomez‐Reino JJ. Interleukin‐6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease‐modifying antirheumatic drugs: The tocilizumab in combination with traditional disease‐modifying antirheumatic drug therapy study. Arthritis Rheum 58: 2968‐2980, 2008.
 73. Ghee JY, Han DH, Song HK, Kim WY, Kim SH, Yoon HE, Choi BS, Kim YS, Kim J, Yang CW. The role of macrophage in the pathogenesis of chronic cyclosporine‐induced nephropathy. Nephrol Dial Transplant 23: 4061‐4069, 2008.
 74. Giannakakis K, Feriozzi S, Perez M, Faraggiana T, Muda AO. Aberrantly glycosylated IgA1 in glomerular immune deposits of IgA nephropathy. J Am Soc Nephrol 18: 3139‐3146, 2007.
 75. Ginzler EM, Aranow C. Mycophenolate mofetil in lupus nephritis. Lupus 14: 59‐64, 2005.
 76. Ginzler EM, Dooley MA, Aranow C, Kim MY, Buyon J, Merrill JT, Petri M, Gilkeson GS, Wallace DJ, Weisman MH, Appel GB. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 353: 2219‐2228, 2005.
 77. Girardin E, Grau GE, Paunier L, Le CC. Early hemodynamic and renal effects of tumor necrosis factor alpha: Role of thromboxane. Circ Shock 42: 20‐26, 1994.
 78. Glassock RJ. The pathogenesis of IgA nephropathy. Curr Opin Nephrol Hypertens 20: 153‐160, 2011.
 79. Gomez‐Guerrero C, Lopez‐Armada MJ, Gonzalez E, Egido J. Soluble IgA and IgG aggregates are catabolized by cultured rat mesangial cells and induce production of TNF‐alpha and IL‐6, and proliferation. J Immunol 153: 5247‐5255, 1994.
 80. Gourley MF, Austin HA, III, Scott D, Yarboro CH, Vaughan EM, Muir J, Boumpas DT, Klippel JH, Balow JE, Steinberg AD. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial. Ann Intern Med 125: 549‐557, 1996.
 81. Goyal A, Crook ED. Thiazolidinediones and progression of renal disease in patients with diabetes. J Investig Med 54: 56‐61, 2006.
 82. Griffin KA, Bidani AK. Progression of renal disease: Renoprotective specificity of renin‐angiotensin system blockade. Clin J Am Soc Nephrol 1: 1054‐1065, 2006.
 83. Gross O, Girgert R, Rubel D, Temme J, Theissen S, Muller GA. Renal protective effects of aliskiren beyond its antihypertensive property in a mouse model of progressive fibrosis. Am J Hypertens 24: 355‐361, 2011.
 84. Guzik TJ, Hoch NE, Brown KA, McCann LA, Rahman A, Dikalov S, Goronzy J, Weyand C, Harrison DG. Role of the T cell in the genesis of angiotensin II induced hypertension and vascular dysfunction. J Exp Med 204: 2449‐2460, 2007.
 85. Haak‐Frendscho M, Marsters SA, Mordenti J, Brady S, Gillett NA, Chen SA, Ashkenazi A. Inhibition of TNF by a TNF receptor immunoadhesin. Comparison to an anti‐TNF monoclonal antibody. J Immunol 152: 1347‐1353, 1994.
 86. Hahn BH, McMahon MA, Wilkinson A, Wallace WD, Daikh DI, Fitzgerald JD, Karpouzas GA, Merrill JT, Wallace DJ, Yazdany J, Ramsey‐Goldman R, Singh K, Khalighi M, Choi SI, Gogia M, Kafaja S, Kamgar M, Lau C, Martin WJ, Parikh S, Peng J, Rastogi A, Chen W, Grossman JM. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken) 64: 797‐808, 2012.
 87. Harrington LE, Hatton RD, Mangan PR, Turner H, Murphy TL, Murphy KM, Weaver CT. Interleukin 17‐producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 6: 1123‐1132, 2005.
 88. Harris RC, Neilson EG. Toward a unified theory of renal progression. Annu Rev Med 57: 365‐380, 2006.
 89. Harrison DG, Guzik TJ, Lob HE, Madhur MS, Marvar PJ, Thabet SR, Vinh A, Weyand CM. Inflammation, immunity, and hypertension. Hypertension 57: 132‐140, 2011.
 90. Hayashi T, Faustman DL. Implications of altered apoptosis in diabetes mellitus and autoimmune disease. Apoptosis 6: 31‐45, 2001.
 91. Heidland A, Sebekova K, Schinzel R. Advanced glycation end products and the progressive course of renal disease. Am J Kidney Dis 38: S100‐S106, 2001.
 92. Herrera J, Ferrebuz A, MacGregor EG, Rodriguez‐Iturbe B. Mycophenolate mofetil treatment improves hypertension in patients with psoriasis and rheumatoid arthritis. J Am Soc Nephrol 17: S218‐S225, 2006.
 93. Higuchi T, Aiba Y, Nomura T, Matsuda J, Mochida K, Suzuki M, Kikutani H, Honjo T, Nishioka K, Tsubata T. Cutting Edge: Ectopic expression of CD40 ligand on B cells induces lupus‐like autoimmune disease. J Immunol 168: 9‐12, 2002.
 94. Hirayama K, Ebihara I, Yamamoto S, Kai H, Muro K, Yamagata K, Kobayashi M, Koyama A. Predominance of type‐2 immune response in idiopathic membranous nephropathy. Cytoplasmic cytokine analysis. Nephron 91: 255‐261, 2002.
 95. Hirschberg R, Wang S. Proteinuria and growth factors in the development of tubulointerstitial injury and scarring in kidney disease. Curr Opin Nephrol Hypertens 14: 43‐52, 2005.
 96. Holdsworth SR, Kitching AR, Tipping PG. Th1 and Th2 T helper cell subsets affect patterns of injury and outcomes in glomerulonephritis. Kidney Int 55: 1198‐1216, 1999.
 97. Holdsworth SR, Neale TJ, Wilson CB. Abrogation of macrophage‐dependent injury in experimental glomerulonephritis in the rabbit. Use of an antimacrophage serum. J Clin Invest 68: 686‐698, 1981.
 98. Holdsworth SR, Summers SA. Role of mast cells in progressive renal diseases. J Am Soc Nephrol 19: 2254‐2261, 2008.
 99. Hou FF, Zhang X, Zhang GH, Xie D, Chen PY, Zhang WR, Jiang JP, Liang M, Wang GB, Liu ZR, Geng RW. Efficacy and safety of benazepril for advanced chronic renal insufficiency. N Engl J Med 354: 131‐140, 2006.
 100. Illei GG, Austin HA, Crane M, Collins L, Gourley MF, Yarboro CH, Vaughan EM, Kuroiwa T, Danning CL, Steinberg AD, Klippel JH, Balow JE, Boumpas DT. Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long‐term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med 135: 248‐257, 2001.
 101. Illei GG, Shirota Y, Yarboro CH, Daruwalla J, Tackey E, Takada K, Fleisher T, Balow JE, Lipsky PE. Tocilizumab in systemic lupus erythematosus: Data on safety, preliminary efficacy, and impact on circulating plasma cells from an open‐label phase I dosage‐escalation study. Arthritis Rheum 62: 542‐552, 2010.
 102. Imano E, Kanda T, Nakatani Y, Nishida T, Arai K, Motomura M, Kajimoto Y, Yamasaki Y, Hori M. Effect of troglitazone on microalbuminuria in patients with incipient diabetic nephropathy. Diabetes Care 21: 2135‐2139, 1998.
 103. Ishikura H, Takahashi C, Kanagawa K, Hirata H, Imai K, Yoshiki T. Cytokine regulation of ICAM‐1 expression on human renal tubular epithelial cells in vitro. Transplantation 51: 1272‐1275, 1991.
 104. Ivanov II, McKenzie BS, Zhou L, Tadokoro CE, Lepelley A, Lafaille JJ, Cua DJ, Littman DR. The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL‐17+ T helper cells. Cell 126: 1121‐1133, 2006.
 105. Jacob N, Yang H, Pricop L, Liu Y, Gao X, Zheng SG, Wang J, Gao HX, Putterman C, Koss MN, Stohl W, Jacob CO. Accelerated pathological and clinical nephritis in systemic lupus erythematosus‐prone New Zealand Mixed 2328 mice doubly deficient in TNF receptor 1 and TNF receptor 2 via a Th17‐associated pathway. J Immunol 182: 2532‐2541, 2009.
 106. Jayne D. Role of rituximab therapy in glomerulonephritis. J Am Soc Nephrol 21: 14‐17, 2010.
 107. Jennette JC, Falk RJ. Pathogenesis of the vascular and glomerular damage in ANCA‐positive vasculitis. Nephrol Dial Transplant 13(Suppl 1): 16‐20, 1998.
 108. Jiang C, Ting AT, Seed B. PPAR‐gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 391: 82‐86, 1998.
 109. Johnson RJ, Raines EW, Floege J, Yoshimura A, Pritzl P, Alpers C, Ross R. Inhibition of mesangial cell proliferation and matrix expansion in glomerulonephritis in the rat by antibody to platelet‐derived growth factor. J Exp Med 175: 1413‐1416, 1992.
 110. Kalunian KC, Davis JC, Jr, Merrill JT, Totoritis MC, Wofsy D. Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti‐CD154: A randomized, double‐blind, placebo‐controlled trial. Arthritis Rheum 46: 3251‐3258, 2002.
 111. Kanamori H, Matsubara T, Mima A, Sumi E, Nagai K, Takahashi T, Abe H, Iehara N, Fukatsu A, Okamoto H, Kita T, Doi T, Arai H. Inhibition of MCP‐1/CCR2 pathway ameliorates the development of diabetic nephropathy. Biochem Biophys Res Commun 360: 772‐777, 2007.
 112. Kenny D, McCarthy‐Kenny G, Pelc LR, Cheung HS, Brooks HL, Warltier DC. Vasodilator actions of interleukin‐1 in the canine coronary circulation. Basic Res Cardiol 85: 279‐284, 1990.
 113. Kielar ML, John R, Bennett M, Richardson JA, Shelton JM, Chen L, Jeyarajah DR, Zhou XJ, Zhou H, Chiquett B, Nagami GT, Lu CY. Maladaptive role of IL‐6 in ischemic acute renal failure. J Am Soc Nephrol 16: 3315‐3325, 2005.
 114. Kliem V, Johnson RJ, Alpers CE, Yoshimura A, Couser WG, Koch KM, Floege J. Mechanisms involved in the pathogenesis of tubulointerstitial fibrosis in 5/6‐nephrectomized rats. Kidney Int 49: 666‐678, 1996.
 115. Knight SF, Imig JD. Obesity, insulin resistance, and renal function. Microcirculation 14: 349‐362, 2007.
 116. Koc M, Toprak A, Arikan H, Odabasi Z, Elbir Y, Tulunay A, Asicioglu E, Eksioglu‐Demiralp E, Glorieux G, Vanholder R, Akoglu E. Toll‐like receptor expression in monocytes in patients with chronic kidney disease and haemodialysis: Relation with inflammation. Nephrol Dial Transplant 26: 955‐963, 2011.
 117. Kohan DE, Merli CA, Simon EE. Micropuncture localization of the natriuretic effect of interleukin 1. Am J Physiol 256: F810‐F813, 1989.
 118. Korgaonkar SN, Feng X, Ross MD, Lu TC, D'Agati V, Iyengar R, Klotman PE, He JC. HIV‐1 upregulates VEGF in podocytes. J Am Soc Nephrol 19: 877‐883, 2008.
 119. Kougias P, Chai H, Lin PH, Lumsden AB, Yao Q, Chen C. Adipocyte‐derived cytokine resistin causes endothelial dysfunction of porcine coronary arteries. J Vasc Surg 41: 691‐698, 2005.
 120. Kumar S, Allen DA, Kieswich JE, Patel NS, Harwood S, Mazzon E, Cuzzocrea S, Raftery MJ, Thiemermann C, Yaqoob MM. Dexamethasone ameliorates renal ischemia‐reperfusion injury. J Am Soc Nephrol 20: 2412‐2425, 2009.
 121. Lai KW, Wei CL, Tan LK, Tan PH, Chiang GS, Lee CG, Jordan SC, Yap HK. Overexpression of interleukin‐13 induces minimal‐change‐like nephropathy in rats. J Am Soc Nephrol 18: 1476‐1485, 2007.
 122. Lanier LL. Up on the tightrope: Natural killer cell activation and inhibition. Nat Immunol 9: 495‐502, 2008.
 123. Lee DL, Sturgis LC, Labazi H, Osborne JB, Jr, Fleming C, Pollock JS, Manhiani M, Imig JD, Brands MW. Angiotensin II hypertension is attenuated in interleukin‐6 knockout mice. Am J Physiol Heart Circ Physiol 290: H935‐H940, 2006.
 124. Lee LK, Meyer TW, Pollock AS, Lovett DH. Endothelial cell injury initiates glomerular sclerosis in the rat remnant kidney. J Clin Invest 96: 953‐964, 1995.
 125. Lekgabe ED, Kiriazis H, Zhao C, Xu Q, Moore XL, Su Y, Bathgate RA, Du XJ, Samuel CS. Relaxin reverses cardiac and renal fibrosis in spontaneously hypertensive rats. Hypertension 46: 412‐418, 2005.
 126. Lepenies J, Eardley KS, Kienitz T, Hewison M, Ihl T, Stewart PM, Cockwell P, Quinkler M. Renal TLR4 mRNA expression correlates with inflammatory marker MCP‐1 and profibrotic molecule TGF‐beta(1) in patients with chronic kidney disease. Nephron Clin Pract 119: c97‐c104, 2011.
 127. Leung JC, Chan LY, Tang SC, Chu KM, Lai KN. Leptin induces TGF‐beta synthesis through functional leptin receptor expressed by human peritoneal mesothelial cell. Kidney Int 69: 2078‐2086, 2006.
 128. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin‐converting‐enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 329: 1456‐1462, 1993.
 129. Li K, Guo D, Zhu H, Hering‐Smith KS, Hamm LL, Ouyang J, Dong Y. Interleukin‐6 stimulates epithelial sodium channels in mouse cortical collecting duct cells. Am J Physiol Regul Integr Comp Physiol 299: R590‐R595, 2010.
 130. Li S, Holdsworth SR, Tipping PG. B7.1 and B7.2 co‐stimulatory molecules regulate crescentic glomerulonephritis. Eur J Immunol 30: 1394‐1401, 2000.
 131. Li Y, Wang Y, Li Q, Chen Y, Sun SZ, Zhang WD, Jia Q. Effect of resistin on vascular endothelium secretion dysfunction in rats. Endothelium 14: 207‐214, 2007.
 132. Libetta C, Rampino T, Palumbo G, Esposito C, Dal CA. Circulating serum lectins of patients with IgA nephropathy stimulate IL‐6 release from mesangial cells. J Am Soc Nephrol 8: 208‐213, 1997.
 133. Lin JJ, Tonshoff B, Bouriquet N, Casellas D, Kaskel FJ, Moore LC. Insulin‐like growth factor‐I restores microvascular autoregulation in experimental chronic renal failure. Kidney Int Suppl 67: S195‐S198, 1998.
 134. Loverre A, Ditonno P, Crovace A, Gesualdo L, Ranieri E, Pontrelli P, Stallone G, Infante B, Schena A, Di PS, Capobianco C, Ursi M, Palazzo S, Battaglia M, Selvaggi FP, Schena FP, Grandaliano G. Ischemia‐reperfusion induces glomerular and tubular activation of proinflammatory and antiapoptotic pathways: Differential modulation by rapamycin. J Am Soc Nephrol 15: 2675‐2686, 2004.
 135. Macanovic M, Sinicropi D, Shak S, Baughman S, Thiru S, Lachmann PJ. The treatment of systemic lupus erythematosus (SLE) in NZB/W F1 hybrid mice; studies with recombinant murine DNase and with dexamethasone. Clin Exp Immunol 106: 243‐252, 1996.
 136. Mache CJ, Acham‐Roschitz B, Fremeaux‐Bacchi V, Kirschfink M, Zipfel PF, Roedl S, Vester U, Ring E. Complement inhibitor eculizumab in atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol 4: 1312‐1316, 2009.
 137. Madhur MS, Lob HE, McCann LA, Iwakura Y, Blinder Y, Guzik TJ, Harrison DG. Interleukin 17 promotes angiotensin II‐induced hypertension and vascular dysfunction. Hypertension 55: 500‐507, 2010.
 138. Malek AM, Greene AL, Izumo S. Regulation of endothelin 1 gene by fluid shear stress is transcriptionally mediated and independent of protein kinase C and cAMP. Proc Natl Acad Sci U S A 90: 5999‐6003, 1993.
 139. Maloney DG, Grillo‐Lopez AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA, Janakiraman N, Foon KA, Liles TM, Dallaire BK, Wey K, Royston I, Davis T, Levy R. IDEC‐C2B8 (Rituximab) anti‐CD20 monoclonal antibody therapy in patients with relapsed low‐grade non‐Hodgkin's lymphoma. Blood 90: 2188‐2195, 1997.
 140. Malyszko J, Malyszko JS, Pawlak K, Mysliwiec M. Resistin, a new adipokine, is related to inflammation and renal function in kidney allograft recipients. Transplant Proc 38: 3434‐3436, 2006.
 141. Masterson R, Hewitson TD, Kelynack K, Martic M, Parry L, Bathgate R, Darby I, Becker G. Relaxin down‐regulates renal fibroblast function and promotes matrix remodelling in vitro. Nephrol Dial Transplant 19: 544‐552, 2004.
 142. Mathieson PW. Immune dysregulation in minimal change nephropathy. Nephrol Dial Transplant 18(Suppl 6): vi26‐vi29, 2003.
 143. Mathis KW, Venegas‐Pont MR, Masterson CW, Wasson KL, Ryan MJ. Blood pressure in a hypertensive mouse model of SLE is not salt‐sensitive. Am J Physiol Regul Integr Comp Physiol 301: R1281‐R1285, 2011.
 144. Matsuda M, Shikata K, Wada J, Sugimoto H, Shikata Y, Kawasaki T, Makino H. Deposition of mannan binding protein and mannan binding protein‐mediated complement activation in the glomeruli of patients with IgA nephropathy. Nephron 80: 408‐413, 1998.
 145. Matsumoto K, Morishita R, Moriguchi A, Tomita N, Yo Y, Nishii T, Nakamura T, Higaki J, Ogihara T. Prevention of renal damage by angiotensin II blockade, accompanied by increased renal hepatocyte growth factor in experimental hypertensive rats. Hypertension 34: 279‐284, 1999.
 146. Mattson DL, James L, Berdan EA, Meister CJ. Immune suppression attenuates hypertension and renal disease in the Dahl salt‐sensitive rat. Hypertension 48: 149‐156, 2006.
 147. McCarthy ET, Sharma R, Sharma M, Li JZ, Ge XL, Dileepan KN, Savin VJ. TNF‐alpha increases albumin permeability of isolated rat glomeruli through the generation of superoxide. J Am Soc Nephrol 9: 433‐438, 1998.
 148. McMurray RW, Elbourne KB, Lagoo A, Lal S. Mycophenolate mofetil suppresses autoimmunity and mortality in the female NZB x NZW F1 mouse model of systemic lupus erythematosus. J Rheumatol 25: 2364‐2370, 1998.
 149. Medzhitov R. Toll‐like receptors and innate immunity. Nat Rev Immunol 1: 135‐145, 2001.
 150. Meyrier A, Condamin MC, Broneer D. Treatment of adult idiopathic nephrotic syndrome with cyclosporin A: Minimal‐change disease and focal‐segmental glomerulosclerosis. Collaborative Group of the French Society of Nephrology. Clin Nephrol 35(Suppl 1): S37‐S42, 1991.
 151. Mezzano S, Aros C, Droguett A, Burgos ME, Ardiles L, Flores C, Schneider H, Ruiz‐Ortega M, Egido J. NF‐kappaB activation and overexpression of regulated genes in human diabetic nephropathy. Nephrol Dial Transplant 19: 2505‐2512, 2004.
 152. Minghini A, Britt LD, Hill MA. Interleukin‐1 and interleukin‐6 mediated skeletal muscle arteriolar vasodilation: In vitro versus in vivo studies. Shock 9: 210‐215, 1998.
 153. Montecucco F, Pende A, Quercioli A, Mach F. Inflammation in the pathophysiology of essential hypertension. J Nephrol 24: 23‐34, 2011.
 154. Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 136: 2348‐2357, 1986.
 155. Mosmann TR, Sad S. The expanding universe of T‐cell subsets: Th1, Th2 and more. Immunol Today 17: 138‐146, 1996.
 156. Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. Nat Rev Immunol 8: 958‐969, 2008.
 157. Muller DN, Shagdarsuren E, Park JK, Dechend R, Mervaala E, Hampich F, Fiebeler A, Ju X, Finckenberg P, Theuer J, Viedt C, Kreuzer J, Heidecke H, Haller H, Zenke M, Luft FC. Immunosuppressive treatment protects against angiotensin II‐induced renal damage. Am J Pathol 161: 1679‐1693, 2002.
 158. Murphy SL, Xu J, Kochanek KD. Deaths: Preliminary Data for 2010. Natl Vital Stat Rep 60: 1‐69, 2012.
 159. Myers BD, Nelson RG, Williams GW, Bennett PH, Hardy SA, Berg RL, Loon N, Knowler WC, Mitch WE. Glomerular function in Pima Indians with noninsulin‐dependent diabetes mellitus of recent onset. J Clin Invest 88: 524‐530, 1991.
 160. Nakamura A, Shikata K, Hiramatsu M, Nakatou T, Kitamura T, Wada J, Itoshima T, Makino H. Serum interleukin‐18 levels are associated with nephropathy and atherosclerosis in Japanese patients with type 2 diabetes. Diabetes Care 28: 2890‐2895, 2005.
 161. Nangaku M, Pippin J, Couser WG. Complement membrane attack complex (C5b‐9) mediates interstitial disease in experimental nephrotic syndrome. J Am Soc Nephrol 10: 2323‐2331, 1999.
 162. Nataraj C, Oliverio MI, Mannon RB, Mannon PJ, Audoly LP, Amuchastegui CS, Ruiz P, Smithies O, Coffman TM. Angiotensin II regulates cellular immune responses through a calcineurin‐dependent pathway. J Clin Invest 104: 1693‐1701, 1999.
 163. Navarro JF, Milena FJ, Mora C, Leon C, Garcia J. Renal pro‐inflammatory cytokine gene expression in diabetic nephropathy: Effect of angiotensin‐converting enzyme inhibition and pentoxifylline administration. Am J Nephrol 26: 562‐570, 2006.
 164. Neeper M, Schmidt AM, Brett J, Yan SD, Wang F, Pan YC, Elliston K, Stern D, Shaw A. Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem 267: 14998‐15004, 1992.
 165. Niemann‐Masanek U, Mueller A, Yard BA, Waldherr R, van der Woude FJ. B7‐1 (CD80) and B7‐2 (CD 86) expression in human tubular epithelial cells in vivo and in vitro. Nephron 92: 542‐556, 2002.
 166. Niemir ZI, Stein H, Noronha IL, Kruger C, Andrassy K, Ritz E, Waldherr R. PDGF and TGF‐beta contribute to the natural course of human IgA glomerulonephritis. Kidney Int 48: 1530‐1541, 1995.
 167. Ninichuk V, Khandoga AG, Segerer S, Loetscher P, Schlapbach A, Revesz L, Feifel R, Khandoga A, Krombach F, Nelson PJ, Schlondorff D, Anders HJ. The role of interstitial macrophages in nephropathy of type 2 diabetic db/db mice. Am J Pathol 170: 1267‐1276, 2007.
 168. Noronha IL, Fujihara CK, Zatz R. The inflammatory component in progressive renal disease–are interventions possible? Nephrol Dial Transplant 17: 363‐368, 2002.
 169. Ohashi K, Iwatani H, Kihara S, Nakagawa Y, Komura N, Fujita K, Maeda N, Nishida M, Katsube F, Shimomura I, Ito T, Funahashi T. Exacerbation of albuminuria and renal fibrosis in subtotal renal ablation model of adiponectin‐knockout mice. Arterioscler Thromb Vasc Biol 27: 1910‐1917, 2007.
 170. Okada S, Shikata K, Matsuda M, Ogawa D, Usui H, Kido Y, Nagase R, Wada J, Shikata Y, Makino H. Intercellular adhesion molecule‐1‐deficient mice are resistant against renal injury after induction of diabetes. Diabetes 52: 2586‐2593, 2003.
 171. Okuda T, Grollman A. Passive transfer of autoimmune induced hypertension in the rat by lymph node cells. Tex Rep Biol Med 25: 257‐264, 1967.
 172. Oldfield V, Dhillon S, Plosker GL. Tocilizumab: A review of its use in the management of rheumatoid arthritis. Drugs 69: 609‐632, 2009.
 173. Olsen F. Transfer of arterial hypertension by splenic cells from DOCA‐salt hypertensive and renal hypertensive rats to normotensive recipients. Acta Pathol Microbiol Scand C 88: 1‐5, 1980.
 174. Ortega LM, Schultz DR, Lenz O, Pardo V, Contreras GN. Review: Lupus nephritis: Pathologic features, epidemiology and a guide to therapeutic decisions. Lupus 19: 557‐574, 2010.
 175. Osuka K, Suzuki Y, Watanabe Y, Dogan A, Takayasu M, Shibuya M, Yoshida J. Vasodilator effects on canine basilar artery induced by intracisternal interleukin‐1 beta. J Cereb Blood Flow Metab 17: 1337‐1345, 1997.
 176. Ouchi N, Kihara S, Arita Y, Okamoto Y, Maeda K, Kuriyama H, Hotta K, Nishida M, Takahashi M, Muraguchi M, Ohmoto Y, Nakamura T, Yamashita S, Funahashi T, Matsuzawa Y. Adiponectin, an adipocyte‐derived plasma protein, inhibits endothelial NF‐kappaB signaling through a cAMP‐dependent pathway. Circulation 102: 1296‐1301, 2000.
 177. Ouedraogo R, Gong Y, Berzins B, Wu X, Mahadev K, Hough K, Chan L, Goldstein BJ, Scalia R. Adiponectin deficiency increases leukocyte‐endothelium interactions via upregulation of endothelial cell adhesion molecules in vivo. J Clin Invest 117: 1718‐1726, 2007.
 178. Panzer U, Kurts C. T cell cross‐talk with kidney dendritic cells in glomerulonephritis. J Mol Med (Berl) 88: 19‐26, 2010.
 179. Pascual G, Fong AL, Ogawa S, Gamliel A, Li AC, Perissi V, Rose DW, Willson TM, Rosenfeld MG, Glass CK. A SUMOylation‐dependent pathway mediates transrepression of inflammatory response genes by PPAR‐gamma. Nature 437: 759‐763, 2005.
 180. Patel NS, Chatterjee PK, Di PR, Mazzon E, Britti D, De SA, Cuzzocrea S, Thiemermann C. Endogenous interleukin‐6 enhances the renal injury, dysfunction, and inflammation caused by ischemia/reperfusion. J Pharmacol Exp Ther 312: 1170‐1178, 2005.
 181. Paust HJ, Turner JE, Steinmetz OM, Peters A, Heymann F, Holscher C, Wolf G, Kurts C, Mittrucker HW, Stahl RA, Panzer U. The IL‐23/Th17 axis contributes to renal injury in experimental glomerulonephritis. J Am Soc Nephrol 20: 969‐979, 2009.
 182. Perez De LG, De WC, Cohen CD, Nieto E, Molina A, Banas B, Luckow B, Vicente AB, Mampaso F, Schlondorff D. Angiotensin inhibition reduces glomerular damage and renal chemokine expression in MRL/lpr mice. J Pharmacol Exp Ther 307: 275‐281, 2003.
 183. Pergola PE, Krauth M, Huff JW, Ferguson DA, Ruiz S, Meyer CJ, Warnock DG. Effect of bardoxolone methyl on kidney function in patients with T2D and Stage 3b‐4 CKD. Am J Nephrol 33: 469‐476, 2011.
 184. Plata‐Salaman CR. Immunoregulators in the nervous system. Neurosci Biobehav Rev 15: 185‐215, 1991.
 185. Ponnuchamy B, Khalil RA. Cellular mediators of renal vascular dysfunction in hypertension. Am J Physiol Regul Integr Comp Physiol 296: R1001‐R1018, 2009.
 186. Purcell ES, Wood GW, Gattone VH. Immune system of the spontaneously hypertensive rat: II. Morphology and function. Anat Rec 237: 236‐242, 1993.
 187. Rajala MW, Obici S, Scherer PE, Rossetti L. Adipose‐derived resistin and gut‐derived resistin‐like molecule‐beta selectively impair insulin action on glucose production. J Clin Invest 111: 225‐230, 2003.
 188. Rajala MW, Qi Y, Patel HR, Takahashi N, Banerjee R, Pajvani UB, Sinha MK, Gingerich RL, Scherer PE, Ahima RS. Regulation of resistin expression and circulating levels in obesity, diabetes, and fasting. Diabetes 53: 1671‐1679, 2004.
 189. RamachandraRao SP, Zhu Y, Ravasi T, McGowan TA, Toh I, Dunn SR, Okada S, Shaw MA, Sharma K. Pirfenidone is renoprotective in diabetic kidney disease. J Am Soc Nephrol 20: 1765‐1775, 2009.
 190. Ramesh G, Reeves WB. TNF‐alpha mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity. J Clin Invest 110: 835‐842, 2002.
 191. Ramos MA, Pinera C, Setien MA, Buelta L, de Cos MA, de Francisco AL, Merino R, Arias M. Modulation of autoantibody production by mycophenolate mofetil: Effects on the development of SLE in (NZB x NZW)F1 mice. Nephrol Dial Transplant 18: 878‐883, 2003.
 192. Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R, Newman RA, Hanna N, Anderson DR. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83: 435‐445, 1994.
 193. Rennke HG, Klein PS, Sandstrom DJ, Mendrick DL. Cell‐mediated immune injury in the kidney: Acute nephritis induced in the rat by azobenzenearsonate. Kidney Int 45: 1044‐1056, 1994.
 194. Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids–new mechanisms for old drugs. N Engl J Med 353: 1711‐1723, 2005.
 195. Ricardo SD, van GH, Eddy AA. Macrophage diversity in renal injury and repair. J Clin Invest 118: 3522‐3530, 2008.
 196. Rivero A, Mora C, Muros M, Garcia J, Herrera H, Navarro‐Gonzalez JF. Pathogenic perspectives for the role of inflammation in diabetic nephropathy. Clin Sci (Lond) 116: 479‐492, 2009.
 197. Robertson J, Wu J, Arends J, Zhou C, McMahon J, Torres L, Lou YH. Activation of glomerular basement membrane‐specific B cells in the renal draining lymph node after T cell‐mediated glomerular injury. J Am Soc Nephrol 16: 3256‐3263, 2005.
 198. Rodriguez‐Iturbe B, Quiroz Y, Shahkarami A, Li Z, Vaziri ND. Mycophenolate mofetil ameliorates nephropathy in the obese Zucker rat. Kidney Int 68: 1041‐1047, 2005.
 199. Roland M, Barbet C, Paintaud G, Magdelaine‐Beuzelin C, Diot E, Halimi JM, Lebranchu Y, Nivet H, Buchler M. Mycophenolate mofetil in patients with systemic lupus erythematosus: A prospective pharmacokinetic study. Lupus 18: 441‐447, 2009.
 200. Royall JA, Berkow RL, Beckman JS, Cunningham MK, Matalon S, Freeman BA. Tumor necrosis factor and interleukin 1 alpha increase vascular endothelial permeability. Am J Physiol 257: L399‐L410, 1989.
 201. Ruggenenti P, Cravedi P, Chianca A, Perna A, Ruggiero B, Gaspari F, Rambaldi A, Marasa M, Remuzzi G. Rituximab in Idiopathic Membranous Nephropathy. J Am Soc Nephrol 2012.
 202. Ruiz‐Ortega M, Egido J. Angiotensin II modulates cell growth‐related events and synthesis of matrix proteins in renal interstitial fibroblasts. Kidney Int 52: 1497‐1510, 1997.
 203. Russell JQ, Mooney T, Cohen PL, MacPherson B, Noelle RJ, Budd RC. Anti‐CD40L accelerates renal disease and adenopathy in MRL‐lpr mice in parallel with decreased thymocyte apoptosis. J Immunol 161: 729‐739, 1998.
 204. Safranow K, Dziedziejko V, Rzeuski R, Czyzycka E, Wojtarowicz A, Binczak‐Kuleta A, Jakubowska K, Olszewska M, Ciechanowicz A, Kornacewicz‐Jach Z, Machalinski B, Pawlik A, Chlubek D. Plasma concentrations of TNF‐alpha and its soluble receptors sTNFR1 and sTNFR2 in patients with coronary artery disease. Tissue Antigens 74: 386‐392, 2009.
 205. Sakaguchi S. Regulatory T cells: Key controllers of immunologic self‐tolerance. Cell 101: 455‐458, 2000.
 206. Sakaguchi S, Fukuma K, Kuribayashi K, Masuda T. Organ‐specific autoimmune diseases induced in mice by elimination of T cell subset. I. Evidence for the active participation of T cells in natural self‐tolerance; deficit of a T cell subset as a possible cause of autoimmune disease. J Exp Med 161: 72‐87, 1985.
 207. Sakaguchi S, Wing K, Miyara M. Regulatory T cells ‐ a brief history and perspective. Eur J Immunol 37(Suppl 1): S116‐S123, 2007.
 208. Sakai N, Wada T, Furuichi K, Iwata Y, Yoshimoto K, Kitagawa K, Kokubo S, Kobayashi M, Takeda S, Kida H, Kobayashi K, Mukaida N, Matsushima K, Yokoyama H. p38 MAPK phosphorylation and NF‐kappa B activation in human crescentic glomerulonephritis. Nephrol Dial Transplant 17: 998‐1004, 2002.
 209. Sanchez‐Lozada LG, Tapia E, Johnson RJ, Rodriguez‐Iturbe B, Herrera‐Acosta J. Glomerular hemodynamic changes associated with arteriolar lesions and tubulointerstitial inflammation. Kidney Int Suppl S9‐14, 2003.
 210. Sanz AB, Justo P, Sanchez‐Nino MD, Blanco‐Colio LM, Winkles JA, Kreztler M, Jakubowski A, Blanco J, Egido J, Ruiz‐Ortega M, Ortiz A. The cytokine TWEAK modulates renal tubulointerstitial inflammation. J Am Soc Nephrol 19: 695‐703, 2008.
 211. Sanz AB, Sanchez‐Nino MD, Ramos AM, Moreno JA, Santamaria B, Ruiz‐Ortega M, Egido J, Ortiz A. NF‐kappaB in renal inflammation. J Am Soc Nephrol 21: 1254‐1262, 2010.
 212. Sarafidis PA, Bakris GL. Protection of the kidney by thiazolidinediones: An assessment from bench to bedside. Kidney Int 70: 1223‐1233, 2006.
 213. Sayyed SG, Ryu M, Kulkarni OP, Schmid H, Lichtnekert J, Gruner S, Green L, Mattei P, Hartmann G, Anders HJ. An orally active chemokine receptor CCR2 antagonist prevents glomerulosclerosis and renal failure in type 2 diabetes. Kidney Int 80: 68‐78, 2011.
 214. Schiller JS, Lucas JW, Ward BW, Peregoy JA. Summary health statistics for U.S. adults: National Health Interview Survey, 2010. Vital Health Stat 10: 1‐207, 2012.
 215. Schondorf T, Musholt PB, Hohberg C, Forst T, Lehmann U, Fuchs W, Lobig M, Muller J, Pfutzner A. The fixed combination of pioglitazone and metformin improves biomarkers of platelet function and chronic inflammation in type 2 diabetes patients: Results from the PIOfix study. J Diabetes Sci Technol 5: 426‐432, 2011.
 216. Schott S, Bierhaus A, Schuetz F, Beckhove P, Schneeweiss A, Sohn C, Domschke C. Therapeutic effects of metformin in breast cancer: Involvement of the immune system? Cancer Immunol Immunother 60: 1221‐1225, 2011.
 217. Schwarting A, Moore K, Wada T, Tesch G, Yoon HJ, Kelley VR. IFN‐gamma limits macrophage expansion in MRL‐Fas(lpr) autoimmune interstitial nephritis: A negative regulatory pathway. J Immunol 160: 4074‐4081, 1998.
 218. Schwarting A, Tesch G, Kinoshita K, Maron R, Weiner HL, Kelley VR. IL‐12 drives IFN‐gamma‐dependent autoimmune kidney disease in MRL‐Fas(lpr) mice. J Immunol 163: 6884‐6891, 1999.
 219. Sean EK, Cockwell P. Macrophages and progressive tubulointerstitial disease. Kidney Int 68: 437‐455, 2005.
 220. Shahid M, Francis J, Majid DS. Tumor necrosis factor‐alpha induces renal vasoconstriction as well as natriuresis in mice. Am J Physiol Renal Physiol 295: F1836‐F1844, 2008.
 221. Shalhoub RJ. Pathogenesis of lipoid nephrosis: A disorder of T‐cell function. Lancet 2: 556‐560, 1974.
 222. Shalmi CL, Dutcher JP, Feinfeld DA, Chun KJ, Saleemi KR, Freeman LM, Lynn RI, Wiernik PH. Acute renal dysfunction during interleukin‐2 treatment: Suggestion of an intrinsic renal lesion. J Clin Oncol 8: 1839‐1846, 1990.
 223. Shao J, Nangaku M, Miyata T, Inagi R, Yamada K, Kurokawa K, Fujita T. Imbalance of T‐cell subsets in angiotensin II‐infused hypertensive rats with kidney injury. Hypertension 42: 31‐38, 2003.
 224. Sharma K, Cook A, Smith M, Valancius C, Inscho EW. TGF‐beta impairs renal autoregulation via generation of ROS. Am J Physiol Renal Physiol 288: F1069‐F1077, 2005.
 225. Shimada K, Yazaki Y. Binding sites for angiotensin II in human mononuclear leucocytes. J Biochem 84: 1013‐1015, 1978.
 226. Shimizu H, Maruyama S, Yuzawa Y, Kato T, Miki Y, Suzuki S, Sato W, Morita Y, Maruyama H, Egashira K, Matsuo S. Anti‐monocyte chemoattractant protein‐1 gene therapy attenuates renal injury induced by protein‐overload proteinuria. J Am Soc Nephrol 14: 1496‐1505, 2003.
 227. Shimoyama H, Nakajima M, Naka H, Maruhashi Y, Akazawa H, Ueda T, Nishiguchi M, Yamoto Y, Kamitsuji H, Yoshioka A. Up‐regulation of interleukin‐2 mRNA in children with idiopathic nephrotic syndrome. Pediatr Nephrol 19: 1115‐1121, 2004.
 228. Siragy HM, Inagami T, Ichiki T, Carey RM. Sustained hypersensitivity to angiotensin II and its mechanism in mice lacking the subtype‐2 (AT2) angiotensin receptor. Proc Natl Acad Sci U S A 96: 6506‐6510, 1999.
 229. Smeltz RB, Wolf NA, Swanborg RH. Inhibition of autoimmune T cell responses in the DA rat by bone marrow‐derived NK cells in vitro: Implications for autoimmunity. J Immunol 163: 1390‐1397, 1999.
 230. Steinberg AD, Steinberg SC. Long‐term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone only. Arthritis Rheum 34: 945‐950, 1991.
 231. Stenvinkel P, Lonnqvist F, Schalling M. Molecular studies of leptin: Implications for renal disease. Nephrol Dial Transplant 14: 1103‐1112, 1999.
 232. Sugimoto H, Shikata K, Wada J, Horiuchi S, Makino H. Advanced glycation end products‐cytokine‐nitric oxide sequence pathway in the development of diabetic nephropathy: Aminoguanidine ameliorates the overexpression of tumour necrosis factor‐alpha and inducible nitric oxide synthase in diabetic rat glomeruli. Diabetologia 42: 878‐886, 1999.
 233. Sumida K, Ubara Y, Suwabe T, Hayami N, Hiramatsu R, Hasegawa E, Yamanouchi M, Hoshino J, Sawa N, Takemoto F, Takaichi K, Ohashi K. Complete remission of myeloperoxidase‐anti‐neutrophil cytoplasmic antibody‐associated crescentic glomerulonephritis complicated with rheumatoid arthritis using a humanized anti‐interleukin 6 receptor antibody. Rheumatology (Oxford) 50: 1928‐1930, 2011.
 234. Suranyi MG, Guasch A, Hall BM, Myers BD. Elevated levels of tumor necrosis factor‐alpha in the nephrotic syndrome in humans. Am J Kidney Dis 21: 251‐259, 1993.
 235. Suzuki H, Fan R, Zhang Z, Brown R, Hall S, Julian BA, Chatham WW, Suzuki Y, Wyatt RJ, Moldoveanu Z, Lee JY, Robinson J, Tomana M, Tomino Y, Mestecky J, Novak J. Aberrantly glycosylated IgA1 in IgA nephropathy patients is recognized by IgG antibodies with restricted heterogeneity. J Clin Invest 119: 1668‐1677, 2009.
 236. Suzuki K, Han GD, Miyauchi N, Hashimoto T, Nakatsue T, Fujioka Y, Koike H, Shimizu F, Kawachi H. Angiotensin II type 1 and type 2 receptors play opposite roles in regulating the barrier function of kidney glomerular capillary wall. Am J Pathol 170: 1841‐1853, 2007.
 237. Svendsen UG. Evidence for an initial, thymus independent and a chronic, thymus dependent phase of DOCA and salt hypertension in mice. Acta Pathol Microbiol Scand A 84: 523‐528, 1976.
 238. Svendsen UG. Spontaneous hypertension and hypertensive vascular disease in the NZB strain of mice. Acta Pathol Microbiol Scand A 85: 548‐554, 1977.
 239. Taal MW, Omer SA, Nadim MK, Mackenzie HS. Cellular and molecular mediators in common pathway mechanisms of chronic renal disease progression. Curr Opin Nephrol Hypertens 9: 323‐331, 2000.
 240. Takahira R, Yonemura K, Fujise Y, Hishida A. Dexamethasone attenuates neutrophil infiltration in the rat kidney in ischemia/reperfusion injury: The possible role of nitroxyl. Free Radic Biol Med 31: 809‐815, 2001.
 241. Takakuta K, Fujimori A, Chikanishi T, Tanokura A, Iwatsuki Y, Yamamoto M, Nakajima H, Okada M, Itoh H. Renoprotective properties of pirfenidone in subtotally nephrectomized rats. Eur J Pharmacol 629: 118‐124, 2010.
 242. Takeichi N, Hamada J, Takimoto M, Fujiwara K, Kobayashi H. Depression of T cell‐mediated immunity and enhancement of autoantibody production by natural infection with microorganisms in spontaneously hypertensive rats (SHR). Microbiol Immunol 32: 1235‐1244, 1988.
 243. Tang WW, Qi M, Warren JS. Monocyte chemoattractant protein 1 mediates glomerular macrophage infiltration in anti‐GBM Ab GN. Kidney Int 50: 665‐671, 1996.
 244. Tanida M, Iwashita S, Terui N, Ootsuka Y, Shu M, Kang D, Suzuki M. Effect of peripheral administration of leptin on the renal sympathetic nerve activity in high‐fat diet‐related hypertensive rats. Life Sci 78: 1149‐1154, 2006.
 245. Taniguchi Y, Yorioka N, Oda H, Yamakido M. Platelet‐derived growth factor, interleukin (IL)‐1 beta, IL‐6R and tumor necrosis factor‐alpha in IgA nephropathy. An immunohistochemical study. Nephron 74: 652‐660, 1996.
 246. Terada Y, Yamada T, Nakashima O, Sasaki S, Nonoguchi H, Tomita K, Marumo F. Expression of PDGF and PDGF receptor mRNA in glomeruli in IgA nephropathy. J Am Soc Nephrol 8: 817‐819, 1997.
 247. Tesch GH, Lim AK. Recent insights into diabetic renal injury from the db/db mouse model of type 2 diabetic nephropathy. Am J Physiol Renal Physiol 300: F301‐F310, 2011.
 248. Tipping PG, Holdsworth SR. T cells in crescentic glomerulonephritis. J Am Soc Nephrol 17: 1253‐1263, 2006.
 249. Tipton AJ, Baban B, Sullivan JC. Female spontaneously hypertensive rats have greater renal anti‐inflammatory T lymphocyte infiltration than males. Am J Physiol Regul Integr Comp Physiol 303: R359‐R367, 2012.
 250. Tsai S, Shameli A, Santamaria P. CD8+ T cells in autoimmunity. Inmunologia 27: 11‐21, 2008.
 251. Tucci M, Stucci S, Strippoli S, Silvestris F. Cytokine overproduction, T‐cell activation, and defective T‐regulatory functions promote nephritis in systemic lupus erythematosus. J Biomed Biotechnol 2010: 457146, 2010.
 252. Turner JE, Paust HJ, Steinmetz OM, Panzer U. The Th17 immune response in renal inflammation. Kidney Int 77: 1070‐1075, 2010.
 253.Van Bruggen MC, Walgreen B, Rijke TP, Berden JH. Attenuation of murine lupus nephritis by mycophenolate mofetil. J Am Soc Nephrol 9: 1407‐1415, 1998.
 254. Vazquez E, Coronel I, Bautista R, Romo E, Villalon CM, Avila‐Casado MC, Soto V, Escalante B. Angiotensin II‐dependent induction of AT(2) receptor expression after renal ablation. Am J Physiol Renal Physiol 288: F207‐F213, 2005.
 255. Venegas‐Pont M, Manigrasso MB, Grifoni SC, LaMarca BB, Maric C, Racusen LC, Glover PH, Jones AV, Drummond HA, Ryan MJ. Tumor necrosis factor‐alpha antagonist etanercept decreases blood pressure and protects the kidney in a mouse model of systemic lupus erythematosus. Hypertension 56: 643‐649, 2010.
 256. Venegas‐Pont M, Mathis KW, Iliescu R, Ray WH, Glover PH, Ryan MJ. Blood pressure and renal hemodynamic responses to acute angiotension II infusion are enhanced in a female mouse model of systemic lupus erythematosus. Am J Physiol Regul Integr Comp Physiol 301: R1286‐R1292, 2011.
 257. Venegas‐Pont M, Sartori‐Valinotti JC, Maric C, Racusen LC, Glover PH, McLemore GR, Jr, Jones AV, Reckelhoff JF, Ryan MJ. Rosiglitazone decreases blood pressure and renal injury in a female mouse model of systemic lupus erythematosus. Am J Physiol Regul Integr Comp Physiol 296: R1282‐R1289, 2009.
 258. Viel EC, Lemarie CA, Benkirane K, Paradis P, Schiffrin EL. Immune regulation and vascular inflammation in genetic hypertension. Am J Physiol Heart Circ Physiol 298: H938‐H944, 2010.
 259. Vielhauer V, Eis V, Schlondorff D, Anders HJ. Identifying chemokines as therapeutic targets in renal disease: Lessons from antagonist studies and knockout mice. Kidney Blood Press Res 27: 226‐238, 2004.
 260. Wada J, Sugiyama H, Makino H. Pathogenesis of IgA nephropathy. Semin Nephrol 23: 556‐563, 2003.
 261. Walport MJ. Complement and systemic lupus erythematosus. Arthritis Res 4(Suppl 3): S279‐S293, 2002.
 262. Wang X, Huang W, Mihara M, Sinha J, Davidson A. Mechanism of action of combined short‐term CTLA4Ig and anti‐CD40 ligand in murine systemic lupus erythematosus. J Immunol 168: 2046‐2053, 2002.
 263. Wang X, Huang W, Schiffer LE, Mihara M, Akkerman A, Hiromatsu K, Davidson A. Effects of anti‐CD154 treatment on B cells in murine systemic lupus erythematosus. Arthritis Rheum 48: 495‐506, 2003.
 264. Wang Y, Hu Q, Madri JA, Rollins SA, Chodera A, Matis LA. Amelioration of lupus‐like autoimmune disease in NZB/WF1 mice after treatment with a blocking monoclonal antibody specific for complement component C5. Proc Natl Acad Sci U S A 93: 8563‐8568, 1996.
 265. Weisberg SP, Hunter D, Huber R, Lemieux J, Slaymaker S, Vaddi K, Charo I, Leibel RL, Ferrante AW. CCR2 modulates inflammatory and metabolic effects of high‐fat feeding. J Clin Invest 116: 115‐124, 2006.
 266. Wendt TM, Tanji N, Guo J, Kislinger TR, Qu W, Lu Y, Bucciarelli LG, Rong LL, Moser B, Markowitz GS, Stein G, Bierhaus A, Liliensiek B, Arnold B, Nawroth PP, Stern DM, D'Agati VD, Schmidt AM. RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am J Pathol 162: 1123‐1137, 2003.
 267. Wenzel UO, Krebs C, Benndorf R. The angiotensin II type 2 receptor in renal disease. J Renin Angiotensin Aldosterone Syst 11: 37‐41, 2010.
 268. White FN, Grollman A. Autoimmune factors associated with infarction of the kidney. Nephron 1: 93‐102, 1964.
 269. Williams RO, Feldmann M, Maini RN. Anti‐tumor necrosis factor ameliorates joint disease in murine collagen‐induced arthritis. Proc Natl Acad Sci U S A 89: 9784‐9788, 1992.
 270. Wilson C, Nelson R, Nicolson M, Pratley R. Plasma leptin concentrations: No difference between diabetic Pima Indians with and without nephropathy. Diabetologia 41: 861‐862, 1998.
 271. Wilson HM, Walbaum D, Rees AJ. Macrophages and the kidney. Curr Opin Nephrol Hypertens 13: 285‐290, 2004.
 272. Wolf G. New insights into the pathophysiology of diabetic nephropathy: From haemodynamics to molecular pathology. Eur J Clin Invest 34: 785‐796, 2004.
 273. Wooley PH, Dutcher J, Widmer MB, Gillis S. Influence of a recombinant human soluble tumor necrosis factor receptor FC fusion protein on type II collagen‐induced arthritis in mice. J Immunol 151: 6602‐6607, 1993.
 274. Wright JT, Jr, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, Cheek D, Douglas‐Baltimore JG, Gassman J, Glassock R, Hebert L, Jamerson K, Lewis J, Phillips RA, Toto RD, Middleton JP, Rostand SG. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: Results from the AASK trial. JAMA 288: 2421‐2431, 2002.
 275. Xiao H, Heeringa P, Hu P, Liu Z, Zhao M, Aratani Y, Maeda N, Falk RJ, Jennette JC. Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Invest 110: 955‐963, 2002.
 276. Yamashita H, Nagai Y, Takamura T, Nohara E, Kobayashi K. Thiazolidinedione derivatives ameliorate albuminuria in streptozotocin‐induced diabetic spontaneous hypertensive rat. Metabolism 51: 403‐408, 2002.
 277. Yan SF, Ramasamy R, Naka Y, Schmidt AM. Glycation, inflammation, and RAGE: A scaffold for the macrovascular complications of diabetes and beyond. Circ Res 93: 1159‐1169, 2003.
 278. Yasuda H, Leelahavanichkul A, Tsunoda S, Dear JW, Takahashi Y, Ito S, Hu X, Zhou H, Doi K, Childs R, Klinman DM, Yuen PS, Star RA. Chloroquine and inhibition of Toll‐like receptor 9 protect from sepsis‐induced acute kidney injury. Am J Physiol Renal Physiol 294: F1050‐F1058, 2008.
 279. Yee CS, Gordon C, Dostal C, Petera P, Dadoniene J, Griffiths B, Rozman B, Isenberg DA, Sturfelt G, Nived O, Turney JH, Venalis A, Adu D, Smolen JS, Emery P. EULAR randomised controlled trial of pulse cyclophosphamide and methylprednisolone versus continuous cyclophosphamide and prednisolone followed by azathioprine and prednisolone in lupus nephritis. Ann Rheum Dis 63: 525‐529, 2004.
 280. Yoshimoto T, Naruse M, Nishikawa M, Naruse K, Tanabe A, Seki T, Imaki T, Demura R, Aikawa E, Demura H. Antihypertensive and vasculo‐ and renoprotective effects of pioglitazone in genetically obese diabetic rats. Am J Physiol 272: E989‐E996, 1997.
 281. Zafiriou S, Stanners SR, Polhill TS, Poronnik P, Pollock CA. Pioglitazone increases renal tubular cell albumin uptake but limits proinflammatory and fibrotic responses. Kidney Int 65: 1647‐1653, 2004.
 282. Zhang B, Ramesh G, Uematsu S, Akira S, Reeves WB. TLR4 signaling mediates inflammation and tissue injury in nephrotoxicity. J Am Soc Nephrol 19: 923‐932, 2008.
 283. Zhang Z, Kyttaris VC, Tsokos GC. The role of IL‐23/IL‐17 axis in lupus nephritis. J Immunol 183: 3160‐3169, 2009.
 284. Zhang ZX, Wang S, Huang X, Min WP, Sun H, Liu W, Garcia B, Jevnikar AM. NK cells induce apoptosis in tubular epithelial cells and contribute to renal ischemia‐reperfusion injury. J Immunol 181: 7489‐7498, 2008.
 285. Zheng L, Sinniah R, Hsu SI. In situ glomerular expression of activated NF‐kappaB in human lupus nephritis and other non‐proliferative proteinuric glomerulopathy. Virchows Arch 448: 172‐183, 2006.
 286. Zhu B, Chen N, Lin Y, Ren H, Zhang W, Wang W, Pan X, Yu H. Mycophenolate mofetil in induction and maintenance therapy of severe lupus nephritis: A meta‐analysis of randomized controlled trials. Nephrol Dial Transplant 22: 1933‐1942, 2007.
 287. Zhu XY, Chade AR, Krier JD, Daghini E, Lavi R, Guglielmotti A, Lerman A, Lerman LO. The chemokine monocyte chemoattractant protein‐1 contributes to renal dysfunction in swine renovascular hypertension. J Hypertens 27: 2063‐2073, 2009.
 288. Ziyadeh FN. Mediators of diabetic renal disease: The case for tgf‐Beta as the major mediator. J Am Soc Nephrol 15(Suppl 1): S55‐S57, 2004.
 289. Zoja C, Donadelli R, Colleoni S, Figliuzzi M, Bonazzola S, Morigi M, Remuzzi G. Protein overload stimulates RANTES production by proximal tubular cells depending on NF‐kappa B activation. Kidney Int 53: 1608‐1615, 1998.

Related Articles:

Immunity and Inflammation

Contact Editor

Submit a note to the editor about this article by filling in the form below.

* Required Field

How to Cite

John D. Imig, Michael J. Ryan. Immune and Inflammatory Role in Renal Disease. Compr Physiol 2013, 3: 957-976. doi: 10.1002/cphy.c120028